50 Participants Needed

Cardiac Rehabilitation for Cardiac Amyloidosis

(CAPACITY Trial)

DB
Overseen ByDana B Amaro, RN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Wake Forest University Health Sciences
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should be on stable treatment for their cardiac amyloidosis or under active surveillance, which suggests you may continue your current medications.

What data supports the effectiveness of the treatment Cardiac Rehabilitation for Cardiac Amyloidosis?

Cardiac rehabilitation has been shown to improve heart function and overall well-being in patients with heart conditions, such as after a heart attack, by including exercise, diet changes, and stress management. These components can help improve symptoms and quality of life, which may also benefit patients with cardiac amyloidosis.12345

Is cardiac rehabilitation safe for humans?

Exercise-based cardiac rehabilitation is generally safe and well-tolerated in humans, including those with heart disease and cancer. It has been shown to improve fitness and reduce cardiovascular risks, with no significant safety concerns reported in the studies reviewed.678910

How is the Cardiac Rehabilitation treatment for Cardiac Amyloidosis different from other treatments?

Cardiac Rehabilitation for Cardiac Amyloidosis is unique because it combines structured exercise, risk factor management, psychological support, and nutrition counseling to improve heart health and overall well-being, unlike traditional treatments that may not address these aspects comprehensively. This approach is particularly beneficial for patients with cancer-related heart issues, as it helps counteract the negative effects of cancer therapies on the heart.6791112

Research Team

JS

Jai Singh, MD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

The CAPACITY study is for adults over 18 with mild to moderate heart failure who can exercise and commit to a cardiac rehab program. They should be on stable treatment or monitored for cardiac amyloidosis, have a life expectancy of at least 6 months, and be able to attend thrice-weekly sessions.

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
Participant must be able and willing to follow the cardiac rehabilitation activities
My heart condition is being actively monitored or treated without changes.
See 4 more

Exclusion Criteria

I have trouble walking or have fallen before.
Inability to provide informed consent
I have severe heart failure.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Testing

Baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing

1 week
1 visit (in-person)

Treatment

Supervised cardiac rehabilitation program including planned 3 one-hour sessions a week for a total of 12 weeks

12 weeks
36 visits (in-person)

Post-Intervention Testing

Post-intervention 6-minute walk test and CPET test performed within 2 weeks of completion of the 12-week program

2 weeks
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Cardiac Rehabilitation
Trial Overview This trial tests the benefits of a structured exercise program (cardiac rehabilitation) in patients with heart failure who still have normal heart pumping function. It aims to see if their fitness and quality of life improve with regular supervised exercise.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: cardiac rehabilitation groupExperimental Treatment1 Intervention
Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
Group II: control group - no interventionActive Control1 Intervention
Control Group will have baseline 6-minute walk test and CPET testing followed by a repeat 6-minute walk test and CPET test in 12-14 weeks

Cardiac Rehabilitation is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Cardiac Rehabilitation for:
  • Cardiovascular disease prevention in cancer survivors
  • Improvement of cardiorespiratory fitness in cancer patients
🇪🇺
Approved in European Union as Cardio-Oncology Rehabilitation for:
  • Reduction of cardiovascular risk in cancer survivors
  • Management of cardiotoxicity related to cancer therapies

Find a Clinic Near You

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials
1,432
Recruited
2,506,000+

Findings from Research

Cardiac rehabilitation, which includes smoking cessation and dietary changes like the Mediterranean diet, can significantly reduce cardiac events and improve overall health outcomes, including hypertension and cancer risk.
Exercise training programs within cardiac rehabilitation enhance functional capacity and symptoms in heart failure patients, highlighting the importance of these multifactorial interventions in post-cardiac event management.
Cardiac rehabilitation: where are we going?Gohlke, H., Gohlke-Bärwolf, C.[2013]
Cardiac rehabilitation (CR) for cancer survivors shows low-to-moderate quality in reporting and moderate-to-high risk of bias, which affects the reliability of the findings and their application in clinical practice.
Despite the quality concerns, survivors who completed CR demonstrated improved cardiorespiratory fitness and reduced fatigue compared to those who did not participate in CR, suggesting potential benefits of the intervention.
Research Quality and Impact of Cardiac Rehabilitation in Cancer Survivors: A Systematic Review and Meta-Analysis.Fakhraei, R., Peck BKin, SS., Abdel-Qadir, H., et al.[2022]
In a study of 1399 patients undergoing cardiac rehabilitation programs, 93% showed improvement in functional capacity, with an average increase of 1.45 METs, indicating the effectiveness of these programs in enhancing heart health.
Patients aged 45-65 and those over 65, as well as those who had coronary artery bypass graft surgery, experienced greater improvements in functional capacity, suggesting that age and type of cardiac event may influence rehabilitation outcomes.
[Predictors of changes in functional capacity on a cardiac rehabilitation program].Branco, CF., Viamonte, S., Matos, C., et al.[2018]

References

Cardiac rehabilitation: where are we going? [2013]
Research Quality and Impact of Cardiac Rehabilitation in Cancer Survivors: A Systematic Review and Meta-Analysis. [2022]
[Predictors of changes in functional capacity on a cardiac rehabilitation program]. [2018]
'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at home- and centre-based cardiac rehabilitation. [2021]
Efficacy of cardiac rehabilitation services. With emphasis on patients after myocardial infarction. [2019]
Cardio-Oncology Rehabilitation-Present and Future Perspectives. [2022]
The core components of cardio-oncology rehabilitation. [2022]
Exercise-based cardiac rehabilitation in patients with coronary heart disease: meta-analysis outcomes revisited. [2022]
Cardio-Oncology rehabilitation- challenges and opportunities to improve cardiovascular outcomes in cancer patients and survivors. [2021]
Cancer and cardiovascular disease: The impact of cardiac rehabilitation and cardiorespiratory fitness on survival. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. [2020]
Cardio-oncology and Cancer Rehabilitation: Is an Integrated Approach Possible? [2023]